Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance

Volume: 160, Pages: 32 - 35
Published: Oct 1, 2021
Abstract
Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown a high response rate and long progression-free survival in primary treatment of ALK-positive non-small-cell lung cancer (NSCLC). De novo resistance or refractory subtype is rare event. Herein, we identify the first case with serial next-generation sequencing (NGS) results that harboured a rare echinoderm microtubule associated protein like 4 gene (EML4) -ALK...
Paper Details
Title
Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance
Published Date
Oct 1, 2021
Volume
160
Pages
32 - 35
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.